Zevra Therapeutics (ZVRA) Receivables - Net (2016 - 2026)

Zevra Therapeutics (ZVRA) has 11 years of Receivables - Net data on file, last reported at $22.1 million in Q1 2026.

• Quarterly Receivables - Net rose 75.14% year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (up 75.14% YoY) and the FY2025 annual result came in at $23.3 million, up 121.32% from the prior year.
• Receivables - Net slipped to $22.1 million in Q1 2026, from $23.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $23.3 million in Q4 2025 to a low of $2.8 million in Q2 2022.
• A 5-year average of $11.7 million and a median of $9.9 million in 2023 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 443.13% in 2022, down 70.64% in 2022.
• Tracing ZVRA's Receivables - Net over 5 years: stood at $8.3 million in 2022, then surged by 109.39% to $17.4 million in 2023, then plunged by 39.52% to $10.5 million in 2024, then soared by 121.32% to $23.3 million in 2025, then dropped by 4.99% to $22.1 million in 2026.
• The last three Receivables - Net figures came in at $22.1 million (Q1 2026), $23.3 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.